Piperacillin/Tazobactam Continuous infusion — Competitive Intelligence Brief

Piperacillin/Tazobactam Continuous infusion (Piperacillin/Tazobactam Continuous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam/beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); beta-lactamases Infectious Disease Small molecule

Target snapshot

Piperacillin/Tazobactam Continuous infusion (Piperacillin/Tazobactam Continuous infusion) — Ain Shams University. Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Piperacillin/Tazobactam Continuous infusion TARGET	Piperacillin/Tazobactam Continuous infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); beta-lactamases
treatment with CAZ-AVI	treatment with CAZ-AVI	Southeast University, China	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins and serine beta-lactamases
Ceftazidime-avibactam + Sulbactam	Ceftazidime-avibactam + Sulbactam	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
Piperacillin/Tazobactam Intermittent infusion	Piperacillin/Tazobactam Intermittent infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Levofloxacin-Amox/clav.	Levofloxacin-Amox/clav.	Buddhist Tzu Chi General Hospital	marketed	Fluoroquinolone + Beta-lactam/Beta-lactamase inhibitor combination	Bacterial DNA gyrase, topoisomerase IV, penicillin-binding proteins
Ceftazidime-avibactam	Ceftazidime-avibactam	Qilu Pharmaceutical Co., Ltd.	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); serine beta-lactamases
CAZ/AVI	CAZ/AVI	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam/beta-lactamase inhibitor combination class)

1. National University of Singapore · 2 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
5. Southeast University, China · 1 drug in this class
6. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
7. Wockhardt · 1 drug in this class
8. Ivan Šitum, MD · 1 drug in this class